Announcement • Jun 18
AEON Biopharma, Inc. Elects Each of Marc Forth and Seongsoo Park as Class III Directors of the Company's Board of Directors AEON Biopharma, Inc. at its Annual Meeting of Stockholders on June 17, 2026 elected each of Marc Forth and Seongsoo Park as Class III directors of the Company’s board of directors (the “Class III Directors”) for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029 and until their respective successors have been duly elected and qualified. Announcement • Jun 04
Aeon Biopharma Presents Data Demonstrating Structural and Functional Comparability of Abp-450 to Botox At the 68Th Annual Scientific Meeting of the American Headache Society AEON Biopharma had announced the presentation of new analytical and functional data supporting biosimilarity of ABP-450 to BOTOX at the 68th Annual Scientific Meeting of the American Headache Society, being held June 4-7, 2026 in Orlando, Florida. The poster is being presented by Chad K. Oh, M.D., AEON's Chief Medical Officer. The data being presented builds on previously reported primary structure findings by adding functional evidence demonstrating highly similar biological activity between ABP-450 and BOTOX across multiple orthogonal analytical approaches: genomic sequence alignment, LC-MS peptide mapping, and the LD50 potency assay. LC-MS peptide mapping demonstrated 93%-99% sequence coverage across the core neurotoxin (BoNT/A1) and accessory proteins (NTNH, HA70, HA33, and HA17), with no variant peptides observed between ABP-450 and BOTOX. In the LD50 potency assay, all ABP-450 lots fell within predefined equivalence criteria established from BOTOX reference results, reinforcing functional similarity and further strengthening the analytical foundation supporting biosimilarity. The AHS Annual Scientific Meeting is a leading forum for headache specialists and a central venue for advancing clinical and scientific dialogue in chronic migraine, the largest therapeutic indication for botulinum toxin. BOTOX is currently the only botulinum toxin therapy approved for the treatment of chronic migraine. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name Jeuveau. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. Announcement • Apr 27
AEON Biopharma, Inc., Annual General Meeting, Jun 17, 2026 AEON Biopharma, Inc., Annual General Meeting, Jun 17, 2026. Location: 5 park plaza, suite 1750, irvine United States 
